For the quarter ending 2025-09-30, XNCR had -$16,149K decrease in cash & cash equivalents over the period. -$31,000K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -6,027 | -79,457 |
| Depreciation and amortization | 2,589 | 5,346 |
| Accretion of discount on marketable debt securities, net | 1,652 | 1,489 |
| Stock-based compensation | 10,092 | 22,950 |
| Gain on sale of marketable securities, net | -407 | 5,380 |
| Change in fair value of marketable equity securities | 44,608 | 528 |
| Asset impairment charges | 1,565 | 6,723 |
| Non-cash royalty revenue related to the sale of future royalties | 20,997 | 36,831 |
| Non-cash interest expense on liabilities related to the sale of future royalties | 7,663 | 16,906 |
| Accounts receivable | -19,896 | -14,636 |
| Prepaid expenses and other assets | -5,257 | -3,504 |
| Accounts payable | -9,454 | 3,810 |
| Accrued expenses | 4,223 | 2,631 |
| Operating lease, net | 13 | 877 |
| Other assets and liabilities, net | -216 | 6,287 |
| Net cash used in operating activities | -30,817 | -52,589 |
| Purchase of marketable debt securities | 84,235 | 176,810 |
| Purchase of property and equipment | 183 | 1,827 |
| Purchase of patents | 0 | 0 |
| Proceeds from sales of marketable equity securities | 379 | 13,399 |
| Proceeds from sales and maturities of marketable debt securities | 98,707 | 219,382 |
| Net cash provided by (used in) investing activities | 14,668 | 54,144 |
| Proceeds from the exercises of stock options | 0 | 2,974 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 0 | 662 |
| Proceeds from issuance of common stock and pre-funded warrants | 0 | - |
| Common stock and pre-funded warrants issuance costs | 0 | - |
| Cash paid to acquire noncontrolling interest | 0 | 1,725 |
| Net cash provided by financing activities | 0 | 1,911 |
| Net decrease in cash, cash equivalents, and restricted cash | -16,149 | 3,466 |
| Cash and cash equivalents at beginning of period | 41,262 | - |
| Cash and cash equivalents at end of period | 28,579 | - |
Xencor Inc (XNCR)
Xencor Inc (XNCR)